Osteocyte mitochondria inhibit tumor development via STING-dependent antitumor immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38232158.
- Also identified by DOI 10.1126/sciadv.adi4298 and PMC identifier 10793952.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bone is one of the most common sites of tumor metastases. During the last step of bone metastasis, cancer cells colonize and disrupt the bone matrix, which is maintained mainly by osteocytes, the most abundant cells in the bone microenvironment. However, the role of osteocytes in bone metastasis is still unclear. Here, we demonstrated that osteocytes transfer mitochondria to metastatic cancer cells and trigger the cGAS/STING-mediated antitumor response. Blocking the transfer of mitochondria by specifically knocking out mitochondrial Rho GTPase 1 (<i>Rhot1</i>) or mitochondrial mitofusin 2 (<i>Mfn2</i>) in osteocytes impaired tumor immunogenicity and consequently resulted in the progression of metastatic cancer toward the bone matrix. These findings reveal the protective role of osteocytes against cancer metastasis by transferring mitochondria to cancer cells and potentially offer a valuable therapeutic strategy for preventing bone metastasis.
Medical subject headings
- Osteocytes
- Bone Neoplasms